

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Abiraterone for the treatment of metastatic castrate-resistant prostate cancer

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Janssen (abiraterone) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Black Health Agency • Bob Champion Cancer Trust • CANCERactive • Cancer Black Care • Cancer Equality • Chinese National Healthy Living Centre • Counsel and Care • Equalities National Council • Everyman • Helen Rollason Heal Cancer Charity • Macmillan Cancer Support • Maggie's Centres • Marie Curie Cancer Care • Muslim Council of Britain • Muslim Health Network • Orchid • PCaSO – Prostate Cancer Network • Prostate Cancer Charity • Prostate Cancer Support Federation • Prostate Help Association • South Asian Health Foundation • Specialised Healthcare Alliance • Sue Ryder Care • Tenovus <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians 	<p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Public Health Wales NHS Trust • Scottish Medicines Consortium <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • Hospira (mitoxantrone) • Sandoz (mitoxantrone) • Teva UK (mitoxantrone) • Wockhardt (mitoxantrone) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Prostatic Diseases and Urologic Cancers Group • CORE – Digestive Disorders Foundation • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Association for Services to the Elderly • British Association of Urological Nurses • British Association of Urological Surgeons • British Geriatrics Society • British Prostate Group • British Psychosocial Oncology Society • British Uro-Oncology Group • Cancer Networks Pharmacists Forum • Cancer Research UK • National Pharmacy Association • Pelican Cancer Foundation • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • United Kingdom Clinical Pharmacy Association • United Kingdom Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Hertfordshire • NHS Bradford and Airedale • Welsh Government 	<ul style="list-style-type: none"> • National Institute of Health Research • Ovarian & Prostate Cancer Research Trust • Policy Research Institute on Ageing and Ethnicity • Prostate Action • Pro Cancer Research Fund • Research Institute of the Care of Older People <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • Warwick Evidence • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Cancer <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • tbc

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, Care Quality Commission and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.